文献速递病毒性肝炎艾滋病与性传播感染

慢性丙型肝炎患者携带IFNL4-ΔG并获持续病毒学应答后的代谢变化

Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy.
PubMed 文献 · J Infect Dis · 2020-01-01

本研究在5个临床时间点纵向追踪慢性丙型肝炎患者接受直接抗病毒药物(DAA)治疗后的代谢与炎症指标变化。研究发现平均LDL在DAA治疗期间显著升高,至持续病毒学应答(SVR)后第1年回落,且该变化在携带IFNL4-ΔG等位基因者与TT/TT基因型者之间不同;HIV合并感染状态不影响上述代谢与炎症结局。

要点

  • DAA治疗期间平均LDL明显升高,SVR后第1年回落。
  • LDL变化因IFNL4基因型而异,提示干扰素-λ4参与代谢改变。
  • HIV合并感染状态对代谢与炎症结局无明显影响。

核心结论

  • 获得SVR的慢性丙型肝炎患者LDL变化因IFNL4基因型不同而异,提示干扰素-λ4蛋白参与HCV感染者的代谢变化。

研究设计与样本

  • 纵向研究,采用一般线性模型对重复测量数据进行分析,在5个临床时间点评估慢性丙型肝炎患者的代谢与炎症指标,并按HIV合并感染状态和IFNL4基因型分层。

主要发现

  • 平均LDL在DAA治疗期间由治疗前86.6 mg/dL升至107.4 mg/dL(P < .0001),至SVR后第1年降至97.7 mg/dL(与DAA期比较P < .001,与SVR比较P = .0013)。
  • 携带IFNL4-ΔG等位基因者平均LDL在治疗期间升高、SVR后第1年下降,而TT/TT基因型者在DAA治疗期间及之后未见变化。
  • 平均ALT和AST在治疗前至DAA期间迅速恢复正常,仅平均ALT持续下降至SVR后。
  • 代谢与炎症结局在HIV合并感染状态间相似。

临床怎么用

  • 对接受DAA治疗的慢性丙型肝炎患者,应关注治疗期间及SVR后血脂变化,尤其携带IFNL4-ΔG者。
  • HIV合并感染状态不改变上述代谢随访要点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clearance of hepatitis C virus (HCV) results in rapid changes in metabolic parameters early in direct-acting antiviral (DAA) therapy. Long-term changes after sustained virologic response (SVR) remain unknown. METHODS: We investigated longitudinal changes in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein, triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) using a general linear model for repeated measurements at 5 clinical time points and by human immunodeficiency virus (HIV) coinfection and IFNL4 genotype. RESULTS: The mean LDL increased markedly during DAA therapy (pre-DAA, 86.6 to DAA, 107.4 mg/dL; P < .0001), but then it decreased to 97.7 mg/dL by post-SVR year 1 (P < .001 compared with DAA; P = .0013 compared with SVR). In patients who carry the IFNL4-ΔG allele, mean LDL increased during treatment, then decreased at post-SVR year 1; however, in patients with TT/TT, genotype did not change during and after DAA treatment. The mean ALT and AST normalized rapidly between pre-DAA and DAA, whereas only mean ALT continued to decrease until post-SVR. Metabolic and inflammatory outcomes were similar by HIV-coinfection status. CONCLUSIONS: Changes in LDL among CHC patients who achieved SVR differed by IFNL4 genotype, which implicates the interferon-λ4 protein in metabolic changes observed in HCV-infected patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Emmanuel B, El-Kamary SS, Magder LS, et al. Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. J Infect Dis. 2020. PMID: 31504644. doi:10.1093/infdis/jiz435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。